Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP802787.RAWRXgGOGCEbGhLDigU6UIbho-d26ONlI-1uY7Ub_9QDM130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP802787.RAWRXgGOGCEbGhLDigU6UIbho-d26ONlI-1uY7Ub_9QDM130_provenance.
• NP803103.RAaVB4y2AciFev1DFL6KG9Sus2x3YfCZTI3b0T_S_D_sQ130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP803103.RAaVB4y2AciFev1DFL6KG9Sus2x3YfCZTI3b0T_S_D_sQ130_provenance.
• NP945961.RAXC0ksfZWk7itE_xpdfpfbS1WFMiZzXf6GzB41td-3OM130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP945961.RAXC0ksfZWk7itE_xpdfpfbS1WFMiZzXf6GzB41td-3OM130_provenance.
• assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP803018.RAgF4wHlwhprmTj20WCV9jZTd00_2oc4UhVwuqteotYcc130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP803018.RAgF4wHlwhprmTj20WCV9jZTd00_2oc4UhVwuqteotYcc130_provenance.
• NP554235.RAlQxvfQpNiV1OdOKYxmUJBw6MklsmjjJaoego5EcvWYg130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP554235.RAlQxvfQpNiV1OdOKYxmUJBw6MklsmjjJaoego5EcvWYg130_provenance.
• NP945730.RAoXuq8e2xJB6AdO1laiTUXEltvf3ZA7EVrk7P3GfR7jc130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP945730.RAoXuq8e2xJB6AdO1laiTUXEltvf3ZA7EVrk7P3GfR7jc130_provenance.
• NP946046.RArAYG8LVe7zeewGcGG8CXhlG5O6hZqpzkNctkQZ5ULIA130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP946046.RArAYG8LVe7zeewGcGG8CXhlG5O6hZqpzkNctkQZ5ULIA130_provenance.
• NP1106393.RAjPyStFmHBB6toLzSBY1c5Hb7mTlRRcXKsUsRBOTJQ2k130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1106393.RAjPyStFmHBB6toLzSBY1c5Hb7mTlRRcXKsUsRBOTJQ2k130_provenance.
• NP1106396.RAobo_T2ZeRhZkfefeb7TBIm0QtGvMJXULvn_69LzW45s130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1106396.RAobo_T2ZeRhZkfefeb7TBIm0QtGvMJXULvn_69LzW45s130_provenance.
• NP1106397.RAoYs4GKfifchfQQpXe-CaC6xei__Soh0rUDoB-DBpqOY130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1106397.RAoYs4GKfifchfQQpXe-CaC6xei__Soh0rUDoB-DBpqOY130_provenance.
• NP1106399.RAkWTyAZECe4t4A7DOMueVCn5oIx1OVytNJiD1GHmDtt0130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1106399.RAkWTyAZECe4t4A7DOMueVCn5oIx1OVytNJiD1GHmDtt0130_provenance.
• NP553897.RA9VI7s1mv5eOGywG6O6_eirXQGu8erGPRzcAntKtPfJk130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP553897.RA9VI7s1mv5eOGywG6O6_eirXQGu8erGPRzcAntKtPfJk130_provenance.
• NP554364.RA24r5hc-ByvLyGw403YahfctPgBf81qo6xOAQqR7lrgs130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP554364.RA24r5hc-ByvLyGw403YahfctPgBf81qo6xOAQqR7lrgs130_provenance.
• NP1106398.RAHR4ggd3e3ubgp-FEly0xUC3Qi9O_mWbyd2W-qluP7qs130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1106398.RAHR4ggd3e3ubgp-FEly0xUC3Qi9O_mWbyd2W-qluP7qs130_provenance.
• NP1106400.RAI2V6eGa-hS7SFoogdSyZ3_cqXMCBw4Xkxryxedcfjis130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1106400.RAI2V6eGa-hS7SFoogdSyZ3_cqXMCBw4Xkxryxedcfjis130_provenance.
• NP1106401.RAOi7tuS0-6cBgXSJ8K9-_du2Qkxp1B49cQ4reEemb90Y130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1106401.RAOi7tuS0-6cBgXSJ8K9-_du2Qkxp1B49cQ4reEemb90Y130_provenance.
• NP1106392.RAxj9H_kxrKrxtQ95MA4f3tgESORTZ1nLRUDKi5SNjASM130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1106392.RAxj9H_kxrKrxtQ95MA4f3tgESORTZ1nLRUDKi5SNjASM130_provenance.
• NP1106395.RA1Xi_9_GnfEGLIcZEgXxrTzh1sH5MsWjVIXmp6qCXkmU130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1106395.RA1Xi_9_GnfEGLIcZEgXxrTzh1sH5MsWjVIXmp6qCXkmU130_provenance.